We’ve read the ABHI survey of UK MedTech companies and it signals more pain than gain as NHS and Brexit Contrive to make life tricky
Medtech company website survey unearths a few bad habits
So the deed has been done, UK powers need to get on with the job of leaving the EU, while not actually leaving the EU
Gaining and protecting market share is about so much more than the product and its price. Educational support looks like the ultimate added value alternative
Pick an industry, any industry, and tell us it outstrips medtech in terms of development. We pick furniture. Medtech wins.
When a new survey of regulatory officers highlights their concerns about regulatory rules, should we be surprised?
Goodness knows how much money has gone the way of Google’s Glass experiment, but as a deliberate way of seeing … continue reading “What can Medtech Learn from Google Glass?”
Which therapy turned out to have rather less efficacy than we’d all become convinced it would have? We think it deserves its own award.
We’re getting properly fixated on the power of social media in healthcare, especially medtech marketing. Can we therefore steal ideas from the powerhouse retailers?
This week’s editorial states what we’d hope is the obvious. Medical Technology is an essential component in delivering tomorrow’s healthcare.
Medtech companies have a long way to go with social media. We’re betting tomorrow’s successes will have got it right. So what are you waiting for?
Opinion piece about how device company front line staff have changed over the years and where that leaves the aspiring product manager.
This week we amuse ourselves drawing parallels between the way behaviour was monitored in Venetian colonies during the fourteenth century, and regulation of today’s medical device industry.
What did the Greeks ever do for us? Well, originate healthcare, really. But did they have in mind a vision of what that might look like in 2014?
The only news in town this week is that Medtronic and Covidien are to merge, forming a new “offshore” entity. Strategic fit good: Tick. Tax consequences good: Tick.
Robotically assisted surgery is in the spotlight again as one commentator says it doesn’t justify its cost. Our weekly editorial discusses whether providers have much choice about whether to invest if they’re to remain current and competitive.